FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes

E-ISSN： 1532-6535|97|1|29-36

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.1, 2015-01, pp. : 29-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA Review Divisions: Performance Levels and the Impact on Drug Sponsors

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 393-404

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 281-285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Catalyzing the critical path initiative: FDA's progress in drug development activities

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 3, 2015-03 ,pp. : 221-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 7, 2015-07 ,pp. : 709-715

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Impact of Preclinical Irreproducibility on Drug Development

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 1, 2015-01 ,pp. : 16-18

John Wiley & Sons Inc

Access to resources Recommend Favorite